Scandinavian journal of gastroenterology
-
Scand. J. Gastroenterol. · Oct 2012
Randomized Controlled TrialDouble-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.
Post-infective irritable bowel syndrome (PI-IBS) is characterized by continuing symptoms of irritable bowel syndrome, typically diarrhea-predominant, following an episode of acute gastroenteritis. There is often an increase in sub-epithelial inflammatory and neuroendocrine cells on colonic mucosal biopsy. Mesalamine is an anti-inflammatory agent, effective in the treatment of inflammatory bowel disease. The goal of this study was to compare mesalamine to placebo on symptoms and quality-of-life (QOL) in PI-IBS. ⋯ There was no significant improvement in global symptoms or overall QOL with mesalamine in patients with PI-IBS.